Skip to main content
Top
Published in: BMC Pediatrics 1/2017

Open Access 01-12-2017 | Research article

Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

Authors: Laila M. Sherief, Osama Dawood, Adel Ali, Hanan S. Sherbiny, Naglaa M. Kamal, Mohamed Elshanshory, Osama Abd Alazez, Mohamed Abd Alhady, Mohamed Nour, Wesam A. Mokhtar

Published in: BMC Pediatrics | Issue 1/2017

Login to get access

Abstract

Background

Early vascular alteration, atherosclerosis and coronary artery disease have emerged as important cardiovascular complications among beta-thalassemia major (B-TM) patients. The aims of the current study were to assess the prevalence of premature atherosclerosis among our B-TM patients, and to investigate the diagnostic value of serum Osteoprotegerin assay as an early biomarker for atherosclerosis.

Methods

This cross-sectional study was conducted at Hematology unit - Pediatric Department, Zagazig University Children Hospital- Egypt in the period from March 2014 to March 2015. A total of 115 children were enrolled in the current study; as sixty-five (65) children with beta thalassemia major aged 5–18 years, on regular blood transfusion regimen represented the patient group. While fifty (50) healthy children, with comparable age and gender, were assigned as control group. All participants were subjected to history taking, thorough clinical examination and laboratory investigations including; complete blood count, liver and kidney function tests, C- reactive protein, lipid profile, serum ferritin and serum Osteoprotegerin (OPG) assay. Also, carotid artery intima media thickness (CAIMT) was performed by duplex ultrasound for patients and controls.

Results

Our B-TM patients were transfusion-dependent for as long as 8.5 ± 3.8 years with significantly higher serum ferritin levels (2490 ± 1579 ng/dl vs 83 ± 32 ng/dl, p = 0.001), C-reactive protein (5.7 ± 5.7 vs 0.9 ± 0.9), liver enzymes and bilirubin when compared to controls. Significantly higher serum triglyceride (128 ± 20 vs 101 ± 7 mg/dL, p = 0.009) and atherogenic index of plasma (0.45 ± 0.12 vs 0.22 ± 0.04, p = 0.001) were recorded in patients than comparisons. On the contrary, total serum cholesterol (116 ± 16 vs 143 ± 5, p < 0.001), low density lipoprotein-cholesterol (LDL-C) (44 ± 9 vs 73 ± 6, p < 0.001) and high density lipoprotein cholesterol (HDL-C) (39 ± 2 vs 61 ± 5, p < 0.001), were significantly lowered in patients versus normal peers. Carotid arteries intima media thickness (CAIMT) of both side were significantly increased for patients (Rt 0.62 ± 0.2 vs. 0.29 ± 0.07 mm, p = 0.001 & Lt 0.66 ± 0.17 vs 0.29 ± 0.05 mm, p = 0.001) when compared with healthy controls, and showed positive correlation with, serum triglyceride, atherogenic index of plasma, and serum Osteoprotegerin levels. ELISA assay of serum Osteoprotegerin (OPG) revealed significantly higher levels for thalassemia patients than matched healthy controls (427 ± 102 vs. 324 ± 126 pg/ml, p = 0.02). Of particular interest is the obvious positive correlation between OPG levels and CAIMT of both sides (Rt r 0.54, p = 0.001 &Lt r 0.479, p = 0.001) and also with serum triglycerides (r 0.374, p = 0.03).

Conclusions

Subclinical atherosclerosis started prematurely in children with beta- thalassemia. Carotid artery intima media thickness represented a simple, accurate and non-invasivemodality for early detection ofatherosclerosis. It was correlated well with serum Osteoprotegerin; this finding highlighted the possible validity of OPG assay as an early predictor of atherosclerosis in thalassemia children.
Literature
1.
go back to reference Hussein G, Fawzy M, Sersfi TE, et al. Rapid detection of beta thalassaemia alleles in Egypt using natural or amplified created restriction sites and direct sequencing: a step in disease control. Hemoglobin. 2007;31(1):49–62.CrossRefPubMed Hussein G, Fawzy M, Sersfi TE, et al. Rapid detection of beta thalassaemia alleles in Egypt using natural or amplified created restriction sites and direct sequencing: a step in disease control. Hemoglobin. 2007;31(1):49–62.CrossRefPubMed
2.
go back to reference Muncie Jr HL, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009;80:339–44.PubMed Muncie Jr HL, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009;80:339–44.PubMed
3.
go back to reference Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in thalassemia patients. Eur J ClinInv. 2002;32 suppl 1:55–60.CrossRef Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in thalassemia patients. Eur J ClinInv. 2002;32 suppl 1:55–60.CrossRef
4.
go back to reference Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.CrossRefPubMed Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.CrossRefPubMed
5.
go back to reference Manios E, Tsivgoulis G, Koroboki E, et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke. 2009;40:1515–8.CrossRefPubMed Manios E, Tsivgoulis G, Koroboki E, et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke. 2009;40:1515–8.CrossRefPubMed
6.
go back to reference Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest. 2005;85:9–23.CrossRefPubMed Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest. 2005;85:9–23.CrossRefPubMed
7.
go back to reference Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res. 2005;58(2):173–8.CrossRefPubMed Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res. 2005;58(2):173–8.CrossRefPubMed
8.
go back to reference Hahalis G, Kremastinos DT, Terzis G, et al. Global vasomotor dysfunction and accelerated vascular aging in b-thalassemia major. Atherosclerosis. 2008;198(2):448–57.CrossRefPubMed Hahalis G, Kremastinos DT, Terzis G, et al. Global vasomotor dysfunction and accelerated vascular aging in b-thalassemia major. Atherosclerosis. 2008;198(2):448–57.CrossRefPubMed
9.
go back to reference Loizou CP, Pattichis CS, Nicolaides AN, Pantziaris M. Manual and automated media and intima thickness measurements of the common carotid artery. IEEE Trans UltrasonFerroelectrFreq Control. 2009;56:983–94.CrossRef Loizou CP, Pattichis CS, Nicolaides AN, Pantziaris M. Manual and automated media and intima thickness measurements of the common carotid artery. IEEE Trans UltrasonFerroelectrFreq Control. 2009;56:983–94.CrossRef
10.
go back to reference Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA. Nontraditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ? Acute Card Care. 2007;9:197–206.CrossRefPubMed Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA. Nontraditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ? Acute Card Care. 2007;9:197–206.CrossRefPubMed
11.
go back to reference Rasmussen LM, Ledet T. Osteoprotegerin and diabetic microangiopathy. Horm Metab Res. 2005;37(1):90–S94.CrossRefPubMed Rasmussen LM, Ledet T. Osteoprotegerin and diabetic microangiopathy. Horm Metab Res. 2005;37(1):90–S94.CrossRefPubMed
12.
go back to reference Zannettino CA, Holding AC, Diamond P, et al. Osteoprotogrin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005;204:714–23.CrossRefPubMed Zannettino CA, Holding AC, Diamond P, et al. Osteoprotogrin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005;204:714–23.CrossRefPubMed
13.
go back to reference Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57–66.CrossRefPubMed Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57–66.CrossRefPubMed
14.
go back to reference Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (−/−) mice. Circulation. 2008;117:411–20.CrossRefPubMedPubMedCentral Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (−/−) mice. Circulation. 2008;117:411–20.CrossRefPubMedPubMedCentral
15.
go back to reference Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosisby inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J ExpMed. 2000;192:463–74.CrossRef Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosisby inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J ExpMed. 2000;192:463–74.CrossRef
16.
go back to reference Borgna-Pignatti C, Galanello R. Wintrobe's clinical hematology. 11. Vol. 42. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 1319–65. Borgna-Pignatti C, Galanello R. Wintrobe's clinical hematology. 11. Vol. 42. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 1319–65.
17.
go back to reference Friedewald W, Levy RI, Freidrickson DS. Estimation of concentration of low-density lipoprotein in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed Friedewald W, Levy RI, Freidrickson DS. Estimation of concentration of low-density lipoprotein in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
18.
go back to reference Gursel O, Kureli AE, Tascilar E, et al. Premature atherosclerosis in children with B thalassemia major. J PediatrHematoloncol. 2012;34(8):630–4. Gursel O, Kureli AE, Tascilar E, et al. Premature atherosclerosis in children with B thalassemia major. J PediatrHematoloncol. 2012;34(8):630–4.
19.
go back to reference Fin AV, Kolodgie VR. Correlation between carotid intima-media thickness and atherosclerosis: a point of view from pathology. AtherisclerThromVascBiol. 2010;30:177–81. Fin AV, Kolodgie VR. Correlation between carotid intima-media thickness and atherosclerosis: a point of view from pathology. AtherisclerThromVascBiol. 2010;30:177–81.
20.
go back to reference Jarvisalo MJ, L. Jartti, K. Nanto-Salonen, K. Irjala, T. Ronnemaa, J. J. Hartiala, D. S. Celermajer, O. T. Raitakari, M. J. Jarvisalo, L. Jartti, K. Nanto-Salonen, K. Irjala, T. Ronnemaa, J. J. Hartiala, D. S. Celermajer, O. T. Raitakari (2001). Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 104 (24):2943–2947.CrossRefPubMed Jarvisalo MJ, L. Jartti, K. Nanto-Salonen, K. Irjala, T. Ronnemaa, J. J. Hartiala, D. S. Celermajer, O. T. Raitakari, M. J. Jarvisalo, L. Jartti, K. Nanto-Salonen, K. Irjala, T. Ronnemaa, J. J. Hartiala, D. S. Celermajer, O. T. Raitakari (2001). Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 104 (24):2943–2947.CrossRefPubMed
21.
go back to reference Cheung TF, Chow PC, Chan GC, et al. Carotid intima media thickness is increased and related to arterial stiffness in patients with beta thalassemia major. Br J Hematol. 2006;135:732–4.CrossRef Cheung TF, Chow PC, Chan GC, et al. Carotid intima media thickness is increased and related to arterial stiffness in patients with beta thalassemia major. Br J Hematol. 2006;135:732–4.CrossRef
22.
go back to reference Tantawy AG, Adly AM, El Maaty GA, et al. Subclinical atherosclerosis in young beta thalassemia patients. Hemoglobin. 2009;33:463–74.CrossRefPubMed Tantawy AG, Adly AM, El Maaty GA, et al. Subclinical atherosclerosis in young beta thalassemia patients. Hemoglobin. 2009;33:463–74.CrossRefPubMed
23.
go back to reference Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta thalassemia major. Circulation. 2002;106:2561–6.CrossRefPubMed Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta thalassemia major. Circulation. 2002;106:2561–6.CrossRefPubMed
24.
go back to reference Reiter CD, Wang X, Tanus-Santos JE, et al. Cell free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med. 2002;8:1383–9.CrossRefPubMed Reiter CD, Wang X, Tanus-Santos JE, et al. Cell free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med. 2002;8:1383–9.CrossRefPubMed
25.
go back to reference Morris CR, Kuypers FA, Gregory J, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y AcadSci. 2005;1054:481–5.CrossRef Morris CR, Kuypers FA, Gregory J, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y AcadSci. 2005;1054:481–5.CrossRef
26.
go back to reference Morris CR, Kim HY, Klings ES, Wood J, et al. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassemia. Br J Hematol. 2015;169(6):887–98.CrossRef Morris CR, Kim HY, Klings ES, Wood J, et al. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassemia. Br J Hematol. 2015;169(6):887–98.CrossRef
27.
go back to reference Ragab SM, Safan MA, Sherif AS. Lipid profile in beta thalassemia children. Menofia Medical J. 2014;27:66–72.CrossRef Ragab SM, Safan MA, Sherif AS. Lipid profile in beta thalassemia children. Menofia Medical J. 2014;27:66–72.CrossRef
28.
go back to reference Borgna-pignatti C, Cappellini M, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40–7.CrossRefPubMed Borgna-pignatti C, Cappellini M, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40–7.CrossRefPubMed
29.
go back to reference Vladislav S, Rapnael H, Caina L. Renal function in children with B-thalassemia major and thalassemia intermedia. PediatrNephrol. 2008;23:1847–51. Vladislav S, Rapnael H, Caina L. Renal function in children with B-thalassemia major and thalassemia intermedia. PediatrNephrol. 2008;23:1847–51.
30.
go back to reference Livrea MA, Tesorere L, Maggio A, et al. Oxidative modification of low-density lipoprotein and atherogenic risk in B-thalassemia. Blood. 1998;92(10):3936–42.PubMed Livrea MA, Tesorere L, Maggio A, et al. Oxidative modification of low-density lipoprotein and atherogenic risk in B-thalassemia. Blood. 1998;92(10):3936–42.PubMed
31.
go back to reference Anca V, Arica S, Ozer C, et al. Serum lipid values in children with beta thalassemia major. PediatTherapeut. 2010;2(5):130–3. Anca V, Arica S, Ozer C, et al. Serum lipid values in children with beta thalassemia major. PediatTherapeut. 2010;2(5):130–3.
32.
go back to reference Mansi M, Aburjai TA. Lipid profile in Jordanian children with beta thalassemia major. Int J HematolOncol. 2008;18:93–8. Mansi M, Aburjai TA. Lipid profile in Jordanian children with beta thalassemia major. Int J HematolOncol. 2008;18:93–8.
33.
go back to reference Paganga G, Evans C, Rule R, et al. The interaction between ruptured erythrocytes and low density lipoproteins. FEBS. 1992;303:154.CrossRef Paganga G, Evans C, Rule R, et al. The interaction between ruptured erythrocytes and low density lipoproteins. FEBS. 1992;303:154.CrossRef
34.
go back to reference Al Quobaili F, Imad E. AbouAsali. Serum levels of lipid and lipoprotein in Syrian patients with B-thalssemia major. Saudi Med J. 2004;25(7):871–5.PubMed Al Quobaili F, Imad E. AbouAsali. Serum levels of lipid and lipoprotein in Syrian patients with B-thalssemia major. Saudi Med J. 2004;25(7):871–5.PubMed
35.
go back to reference Khubchandani A, Solanki V, Solanki M, et al. Estimation of serum lipid profiles in patients with beta thalassemia major. Int J Res Med. 2014;3(2):65–7. Khubchandani A, Solanki V, Solanki M, et al. Estimation of serum lipid profiles in patients with beta thalassemia major. Int J Res Med. 2014;3(2):65–7.
36.
go back to reference Haghpanah S, Davani M, Samadi B, et al. Serum lipid profiles in patients with beta thalassemia major and intermedia in southern Iran. JRMS. 2010;15:150–4.PubMedPubMedCentral Haghpanah S, Davani M, Samadi B, et al. Serum lipid profiles in patients with beta thalassemia major and intermedia in southern Iran. JRMS. 2010;15:150–4.PubMedPubMedCentral
37.
go back to reference Shams S, Ashtiani MT, Monajemzadeh M, Koochakzadeh L, Irani H, Jafari F, Mohseni A. Evaluation of serum insulin, glucose, lipid profile, and liver function in β-thalassemia major patients and their correlation with iron overload. Labmedicine. 2010;41(80):486–9. Shams S, Ashtiani MT, Monajemzadeh M, Koochakzadeh L, Irani H, Jafari F, Mohseni A. Evaluation of serum insulin, glucose, lipid profile, and liver function in β-thalassemia major patients and their correlation with iron overload. Labmedicine. 2010;41(80):486–9.
38.
go back to reference Hartman C, Tamary H, Tamir A, et al. Hypocholesterolemia in children and adolescents with beta-thalassemia intermedia. J Pediatr. 2002;141(4):543–7.CrossRefPubMed Hartman C, Tamary H, Tamir A, et al. Hypocholesterolemia in children and adolescents with beta-thalassemia intermedia. J Pediatr. 2002;141(4):543–7.CrossRefPubMed
39.
go back to reference Ricchi P, Ammirabile M, Spasiano A, et al. Hypocholesterolemia in adult patients with thalassemia: a link with the severity of genotype in thalassemia intermedia patients. Europ J Hematol. 2009;82:219–22.CrossRef Ricchi P, Ammirabile M, Spasiano A, et al. Hypocholesterolemia in adult patients with thalassemia: a link with the severity of genotype in thalassemia intermedia patients. Europ J Hematol. 2009;82:219–22.CrossRef
40.
go back to reference Amendola G, Danise P, Tordisco N, et al. Lipid profile in beta thalassemia intermedia patients: correlation with erythroid bone marrow activity. Int J Lab Hematol. 2007;29:172–6.CrossRefPubMed Amendola G, Danise P, Tordisco N, et al. Lipid profile in beta thalassemia intermedia patients: correlation with erythroid bone marrow activity. Int J Lab Hematol. 2007;29:172–6.CrossRefPubMed
41.
go back to reference Shalev H, Kapelushnik J, Moser A, et al. Hypocholesterolemia in chronic anemia with increased erythropoieticactivity. Am J Hematol. 2007;82:199–202.CrossRefPubMed Shalev H, Kapelushnik J, Moser A, et al. Hypocholesterolemia in chronic anemia with increased erythropoieticactivity. Am J Hematol. 2007;82:199–202.CrossRefPubMed
42.
go back to reference Tselepis DA, Hahalis G, Tellis CC, et al. Plasma level of lipoprotein associated phospholipase A2 are increased in patients with B-thalassemia. J Lipid Res. 2010;51:3331–41.CrossRefPubMedPubMedCentral Tselepis DA, Hahalis G, Tellis CC, et al. Plasma level of lipoprotein associated phospholipase A2 are increased in patients with B-thalassemia. J Lipid Res. 2010;51:3331–41.CrossRefPubMedPubMedCentral
43.
go back to reference Chrysohou C, Panagiotakos DB, Pistavos C, et al. Distribution of serum lipid and lipoprotein in patients with beta thalassemia major: an epidemiological study in young adults from Greece. Lipid Health Dis. 2004;3:3–8.CrossRef Chrysohou C, Panagiotakos DB, Pistavos C, et al. Distribution of serum lipid and lipoprotein in patients with beta thalassemia major: an epidemiological study in young adults from Greece. Lipid Health Dis. 2004;3:3–8.CrossRef
44.
go back to reference Jacobs A. The pathology of iron overload. In: Jacobs A, Wor-wood M, editors. Iron in biochemistry and medicine II. New York: Academic; 1980. p. 427. Jacobs A. The pathology of iron overload. In: Jacobs A, Wor-wood M, editors. Iron in biochemistry and medicine II. New York: Academic; 1980. p. 427.
45.
go back to reference Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in B-thalassemia major: iron overload and depletion of lipid soluble antioxidant. Blood. 1996;88:3608.PubMed Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in B-thalassemia major: iron overload and depletion of lipid soluble antioxidant. Blood. 1996;88:3608.PubMed
46.
go back to reference Susanti E, Donosepoetro M, Patellong I, et al. Differences between several atherogenic parameters in patients with controlled and uncontrolled type 2 Diabetes Mellitus. Med J Indones. 2010;19(2):103–8.CrossRef Susanti E, Donosepoetro M, Patellong I, et al. Differences between several atherogenic parameters in patients with controlled and uncontrolled type 2 Diabetes Mellitus. Med J Indones. 2010;19(2):103–8.CrossRef
47.
48.
go back to reference Daniels LB, Laughlin G, Sarno MJ. Lp- PLA2 is an independent predictor of incident coronary heart disease in apparently healthy older population. J Am Col Cadiol. 2008;51:913–9.CrossRef Daniels LB, Laughlin G, Sarno MJ. Lp- PLA2 is an independent predictor of incident coronary heart disease in apparently healthy older population. J Am Col Cadiol. 2008;51:913–9.CrossRef
49.
go back to reference Burris Ashwood ER, Burns DE. Textbook of clinical chemistry and molecular diagnostics. 4th ed. St louis: Elseiver, Saunders; 2006. Burris Ashwood ER, Burns DE. Textbook of clinical chemistry and molecular diagnostics. 4th ed. St louis: Elseiver, Saunders; 2006.
50.
51.
go back to reference Breland UM, Hollan I, Saatvedt K, et al. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. Rheumatology. 2010;49:1118–27.CrossRefPubMed Breland UM, Hollan I, Saatvedt K, et al. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. Rheumatology. 2010;49:1118–27.CrossRefPubMed
52.
go back to reference Nybo M, Rasmussen LM. The capability of plasma osteoprotegerinas as predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008;159:603–8.CrossRefPubMed Nybo M, Rasmussen LM. The capability of plasma osteoprotegerinas as predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008;159:603–8.CrossRefPubMed
53.
go back to reference Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-ligand and risk for coronary events: a nested case–control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol. 2009;29(6):975–80.CrossRefPubMed Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-ligand and risk for coronary events: a nested case–control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol. 2009;29(6):975–80.CrossRefPubMed
54.
go back to reference Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol. 2012;109:515–20.CrossRefPubMed Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol. 2012;109:515–20.CrossRefPubMed
Metadata
Title
Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker
Authors
Laila M. Sherief
Osama Dawood
Adel Ali
Hanan S. Sherbiny
Naglaa M. Kamal
Mohamed Elshanshory
Osama Abd Alazez
Mohamed Abd Alhady
Mohamed Nour
Wesam A. Mokhtar
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2017
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-017-0820-1

Other articles of this Issue 1/2017

BMC Pediatrics 1/2017 Go to the issue